InnoCare Pharma (HKEX: 09969; SSE: 688428), a pioneering biopharmaceutical company dedicated to the treatment of cancer and autoimmune diseases, is pleased to announce that it will be presenting the most recent clinical data of its FGFR inhibitor gunagratinib (ICP-192) as a potential treatment for cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium. The event will be held in a hybrid format between January 19-21, 2023, in San Francisco, U.S.
The 2023 ASCO GI Cancers Symposium is an unmissable event for those working in the field of gastrointestinal cancer. With the latest groundbreaking research and multidisciplinary strategies, this symposium promises an engaging and thought-provoking exchange of ideas on the latest developments in GI cancer treatment, research and care. Don’t miss out on this unique opportunity to hear from leading experts and gain invaluable insight into this rapidly evolving field.
Gunagratinib, a highly potent and selective inhibitor of the Fibroblast Growth Factor Receptor (FGFR) pathway, has demonstrated promise in a Phase IIa dose-expansion study of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR alterations. This innovative approach to treating the cancer may provide a much-needed breakthrough in the fight against this challenging disease.
On January 20, Professor Ye Guo will present her research on Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract at the Poster Session B. From 12:00 PM -1:30 PM, U.S. Time, Professor Guo will discuss her findings and answer questions. Don’t miss out on the opportunity to learn more about this exciting field!
InnoCare is on a mission to drive meaningful change for cancer and autoimmune disease patients worldwide. We are dedicated to discovering and developing groundbreaking therapies to address unmet medical needs in areas such as lymphoma, solid tumors, and autoimmune diseases. Our commitment to innovation and patient-centric care is reflected in our global presence, with offices in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.